Literature DB >> 6428911

Pharmacodynamic effects of ouabain following single sublingual and intravenous doses in normal subjects.

G G Belz, J Matthews, U Sauer, H Stern, B Schneider.   

Abstract

In this intraindividual, placebo-controlled, double blind study the dynamic effects of single doses of ouabain 0.5 mg i.v. and 12 mg sublingual were compared with those of the vasodilator sublingual nitroglycerin 0.8 mg. In 12 (sublingual) and 6 (i.v.) healthy volunteers, respectively, cardiac performance was assessed for 60 min after administration, using systolic time intervals ( QS2c , PEPc, PEP/LVET), electrical impedance cardiography ( (dZ/dt)/RZ index) and echocardiography (EDD, ESD, FS). After i.v. ouabain the typical positive inotropic glycoside effects appeared (shortening of QS2c , PEPc, and PEP/LVET, increase of (dZ/dt)/RZ and FS, decrease of EDD and ESD). With nitroglycerin preload reduction diminished cardiac performance, as shown by a rise in PEPc and PEP/LVET and depression of (dZ/dt)/RZ. In addition, EDD (not significant) and ESD were somewhat reduced, FS was enhanced, and QS2c tended to shorten. Following sublingual ouabain, QS2c was unchanged, there was an increase in PEPc and PEP/LVET, a decrease in (dZ/dt)/RZ and FS, EDD was unchanged, and ESD rose. By this route the absolute magnitude of the effects was about 1/3 that of the i.v. drug action. The spectrum of effects of sublingual ouabain indicates a reduction in cardiac performance without any detectable inotropic action. The effects seem to be induced by load changes, with an indication of an increase in afterload although an additional preload reduction cannot be excluded. This dose of the drug given by the sublingual route appears, therefore, to alter cardiac function via an effect on the peripheral circulation, although the final mechanism has not yet been elucidated.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6428911     DOI: 10.1007/bf00548756

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  Studies on digitalis. I. Direct effects on peripheral vascular resistance.

Authors:  J ROSS; J A WALDHAUSEN; E BRAUNWALD
Journal:  J Clin Invest       Date:  1960-06       Impact factor: 14.808

2.  A critical review of the systolic time intervals.

Authors:  R P Lewis; S E Rittogers; W F Froester; H Boudoulas
Journal:  Circulation       Date:  1977-08       Impact factor: 29.690

3.  [Pharmacokinetics of g-strophanthin].

Authors:  K Greeff; E Köhler; H Strobach; E Verspohl
Journal:  Verh Dtsch Ges Kreislaufforsch       Date:  1974

4.  Analysis of growth and dose response curves.

Authors:  J E Grizzle; D M Allen
Journal:  Biometrics       Date:  1969-06       Impact factor: 2.571

5.  Time course of the effects of single intravenous doses of digitoxin and digoxin in normal volunteers.

Authors:  G G Belz; P E Aust; B Schneider
Journal:  J Cardiovasc Pharmacol       Date:  1981 Sep-Oct       Impact factor: 3.105

6.  Effects of ouabain on coronary and systemic vascular resistance and myocardial oxygen consumption in patients without heart failure.

Authors:  H DeMots; S H Rahimtoola; J H McAnulty; G A Porter
Journal:  Am J Cardiol       Date:  1978-01       Impact factor: 2.778

7.  Correlation between changes in systolic time intervals and left ventricular end-diastolic diameter after preload reduction. Non-invasive monitoring of pharmacological intervention.

Authors:  J Buch; H Egeblad; P B Hansen; H Kjaergård; S Waldorff; E Steiness
Journal:  Br Heart J       Date:  1980-12

8.  [Vascular effects of digitalis in human extremities (author's transl)].

Authors:  T Brecht; G Bodem; E Schäfer
Journal:  Klin Wochenschr       Date:  1978-05-15

9.  Lack of ouabain effect on pacing-induced myocardial ischemia in patients with coronary artery disease.

Authors:  H S Loeb; N Streitmatter; D Braunstein; W R Jacobs; R P Croke; R M Gunnar
Journal:  Am J Cardiol       Date:  1979-05       Impact factor: 2.778

10.  Effects of adrenergic receptor activation and blockade on the systolic preejection period, heart rate, and arterial pressure in man.

Authors:  W S Harris; C D Schoenfeld; A M Weissler
Journal:  J Clin Invest       Date:  1967-11       Impact factor: 14.808

View more
  1 in total

1.  Uncorrected pre-ejection period: a simple non-invasive measurement for pharmacodynamic screening of inotropic activity.

Authors:  D Rousson; J Galleyrand; M Silie; J P Boissel
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.